Background Treatment of metastatic prostate cancer is associated with high personal and
economic burden. Recently, new treatment options for castration-resistant prostate cancer …

Background Metastatic cancers occur when cancer cells break away from the primary
tumour. One of the most common sites of metastasis is the bone, with several therapeutic …

Abstract Purpose The EORTC QLU-C10D is a new multi-attribute utility instrument derived
from the EORTC QLQ-C30, a widely used cancer-specific quality of life questionnaire. It …

Background To assess contemporary characteristics, hospital admissions, charges, and
mortality in patients with prostate cancer (CaP) who have bone metastases and skeletal …

Objectives To determine whether differential item functioning (DIF) was present in the
EuroQol five-dimensional questionnaire (EQ-5D) used in cancer (non–small cell lung cancer …

Aims: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor,
denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of …

Despite effective skeletal-related event (SRE)-limiting therapies such as zoledronic acid and
denosumab, SREs continue to place a meaningful burden on patients, providers and …

Background The treatment of metastatic castration-resistant prostate cancer has changed
with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess …

Zoledronic acid is the only bisphosphonate approved for the prevention or delay of skeletal-
related events in patients with bone metastases secondary to prostate cancer. Recently, the …

Bisphosphonates reduce the risk of skeletal-related events (SREs; ie spinal cord
compression, pathological fracture, radiation or surgery to the bone, and hypercalcaemia) in …